Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD25 monoclonal antibody BA1106

A human monoclonal antibody directed against CD25 (interleukin-2 receptor subunit alpha; IL-2R alpha; IL-2Ra), with potential antineoplastic activity. Upon administration, anti-CD25 monoclonal antibody BA1106 targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells in the tumor microenvironment (TME) through antibody-dependent cellular cytotoxicity (ADCC) and prevent immunosuppression, thereby increasing the number of effector T (Teff) cells and enhancing anti-tumor immune responses. CD25, the alpha chain of the IL-2 receptor, is highly expressed on Treg cells but not on Teff cells in tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BA 1106
BA-1106
BA1106
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search